Is Trident Texofab overvalued or undervalued?

As of 14 August 2025, Trident Texofab's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued, with a PE Ratio of 115.02, a Price to Book Value of 18.14, and an EV to EBITDA of 67.04. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.
In comparison to its peers, Trident Texofab's valuation metrics stand out unfavorably. For instance, MMTC has a PE Ratio of 131.56, while Lloyds Enterprises has a significantly lower PE of 32.95, highlighting the disparity in valuation among companies in the same sector. Additionally, Trident Texofab's PEG Ratio of 5.46 further emphasizes its overvaluation relative to growth expectations. Despite recent strong stock performance, with a 1-year return of 388.86% compared to the Sensex's 1.89%, the high valuation ratios suggest caution for potential investors.